Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE1: Retigabine in refractory partial-onset seizures
NCT00232596Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in epilepsy comparing Placebo with Retigabine (2 arms). Primary endpoint: Percent Change in the 28-day Total Partial Seizure Frequency From Baseline to the End of the Double-blind Phase at 18 weeks. Started Sep 2005; status: completed.
02
Drugs
retigabine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT00232596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232596.